Technology evaluation: LErafAON, NeoPharm

Curr Opin Mol Ther. 2003 Oct;5(5):547-52.

Abstract

NeoPharm is developing liposome-encapsulated, c-Raf antisense oligodeoxynucleotides (LErafAON) for the potential treatment of various solid tumors, including those that have become resistant to radiation or chemotherapy. Phase I/II trials commenced in March 2001 and were ongoing as of June 2003.

Publication types

  • Evaluation Study

MeSH terms

  • Animals
  • Antineoplastic Agents / metabolism
  • Antineoplastic Agents / therapeutic use*
  • Clinical Trials, Phase I as Topic
  • Humans
  • Liposomes / metabolism*
  • Mice
  • Neoplasms / therapy*
  • Oligodeoxyribonucleotides / adverse effects
  • Oligodeoxyribonucleotides / metabolism
  • Oligodeoxyribonucleotides / pharmacokinetics
  • Oligodeoxyribonucleotides / therapeutic use*
  • Oligodeoxyribonucleotides, Antisense / adverse effects
  • Oligodeoxyribonucleotides, Antisense / genetics
  • Oligodeoxyribonucleotides, Antisense / metabolism
  • Oligodeoxyribonucleotides, Antisense / therapeutic use*
  • Proto-Oncogene Proteins c-raf / genetics
  • Proto-Oncogene Proteins c-raf / metabolism
  • Proto-Oncogene Proteins c-raf / therapeutic use*

Substances

  • Antineoplastic Agents
  • LErafAON
  • Liposomes
  • Oligodeoxyribonucleotides
  • Oligodeoxyribonucleotides, Antisense
  • Proto-Oncogene Proteins c-raf